Embryo Chromosomal Abnormalities & Overseas IVF: Technical Pathways, Eligibility, and Decision Points

Opening: Real consultation scenario (random mechanism)

Clinic Scenario — A 37-year-old female patient placed a thick stack of test reports on the consultation table. She had undergone two previous IVF transfers in her home country: the first resulted in a missed miscarriage at 8 weeks of gestation, and the second ended in implantation failure. Embryo chromosomal analysis showed both embryos were aneuploid (trisomy 16 and 45,X). Her AMH was 1.2 ng/mL, and her antral follicle count (AFC) was 6. She asked, “If I go abroad for IVF, can I screen for chromosomally normal embryos? Can my ovarian reserve still support PGT?”

1. What are Embryo Chromosomal Abnormalities? How Does Overseas IVF Address Them?

Embryo chromosomal abnormalities refer to deviations in the number or structure of chromosomes within embryo cells. Numerical abnormalities (aneuploidy) are most common, such as trisomy 21, trisomy 16, 45,X, etc.; structural abnormalities include translocations, inversions, deletions, and duplications.

The core technology for addressing chromosomal abnormalities in overseas IVF is Preimplantation Genetic Testing (PGT):

• PGT-A (Aneuploidy Screening): Detects numerical abnormalities in all 23 chromosome pairs, suitable for advanced maternal age, recurrent miscarriage, and recurrent implantation failure.
• PGT-SR (Structural Rearrangement Screening): Identifies structural abnormalities such as translocations and inversions, suitable for carriers of balanced translocations and Robertsonian translocations.
• PGT-M (Monogenic Disease Testing): Targets known pathogenic genes, often used in conjunction with PGT-A.

The clinical accuracy of PGT-A is approximately 95–98%, and PGT-SR is approximately 90–95%. However, PGT cannot detect all abnormalities: there is a risk of missing mosaicism (partially normal, partially abnormal), mitochondrial DNA variants, and imprinting gene defects.

2. A Reproductive Medicine Perspective on Embryo Chromosomal Abnormalities

Embryo chromosomal abnormalities are the primary cause of implantation failure and early miscarriage. Clinical data show:

• The embryo aneuploidy rate in women under 35 is approximately 30–40%;
• It rises to 70–80% at ages 40–42;
• Over 90% in women aged 45 and above.

Male factors are equally critical: Elevated sperm DNA fragmentation index (DFI) (>30%) is significantly associated with embryo chromosomal abnormalities. Additionally, oocyte maturity, mitochondrial function, and meiotic spindle integrity directly affect chromosome segregation.

Clinical Decision Logic: For patients under 35 with no history of miscarriage and normal ovarian reserve, PGT-A is not essential; however, for those aged ≥38, with recurrent miscarriage (≥2 episodes), or carriers of chromosomal abnormalities, PGT can significantly reduce the risk of transferring abnormal embryos.

3. Policy and Technical Differences for PGT Across Countries

Regulations, technical accessibility, and costs for PGT vary significantly between countries, directly impacting patient decisions:

Selection Advice: For those with adequate ovarian reserve requiring comprehensive screening, the US or Thailand are primary options; for those with very low ovarian reserve needing only a few embryos tested, countries with liberal policies and lower costs may be considered. However, laboratory quality is more important than the country. It is recommended to verify biopsy techniques (trophectoderm biopsy at blastocyst stage), testing platforms (NGS vs aCGH), and historical data.

4. Most Easily Overlooked Clinical Details

① Mosaic Embryos

Approximately 5–10% of embryos exhibit chromosomal mosaicism (some cells normal, some abnormal). PGT biopsy only samples 5–10 trophectoderm cells, which may miss mosaicism. Transfer of mosaic embryos requires prenatal diagnosis (amniocentesis) for confirmation.

② Mitochondrial DNA and Embryo Developmental Potential

Mitochondrial DNA copy number is related to embryo developmental competence, but currently, PGT cannot standardly assess it. Some labs attempt a “mitochondrial score,” but its clinical value is still under validation.

③ Sperm DNA Fragmentation Index (DFI)

When DFI >30%, embryo aneuploidy rates and miscarriage rates increase significantly. Male factor evaluation should include semen analysis + DFI + chromosome karyotype, rather than routine semen analysis alone.

④ Oocyte Maturity and Meiosis

When oocyte maturation rate (MII rate) after retrieval is <70%, the risk of aneuploidy increases. Ovarian stimulation protocols need individualized adjustment to avoid an excessively high proportion of immature oocytes.

5. Complete Process for Overseas IVF Targeting Chromosomal Abnormalities

From initial consultation to transfer, it typically takes 4–6 months (including the PGT testing cycle):

• Phase 1: Pre-treatment in Home Country (1–3 months)
  Complete chromosome karyotyping for both partners, AMH, FSH, TORCH, semen analysis + DFI, and uterine cavity assessment (ultrasound or hysteroscopy). Genetic counseling to define the PGT strategy.
• Phase 2: Overseas Initial Visit and Registration (1–2 days)
  Bring all test reports, identification documents (passport, visa, notarized marriage certificate). Develop ovarian stimulation protocol, sign PGT informed consent.
• Phase 3: Ovarian Stimulation and Egg Retrieval (approx. 2 weeks)
  Choose antagonist or PPOS protocol based on AMH and AFC. Trigger and retrieve eggs 36 hours later.
• Phase 4: ICSI Fertilization and Blastocyst Culture (5–6 days)
  All mature oocytes undergo ICSI fertilization, culture to D5/D6 blastocysts.
• Phase 5: Biopsy + PGT Testing (2–4 weeks)
  Trophectoderm cell biopsy, analysis using NGS or aCGH platform. Embryos are cryopreserved simultaneously.
• Phase 6: Frozen Embryo Transfer (FET)
  Endometrial preparation (artificial or natural cycle), select chromosomally normal (euploid) embryo for transfer.
• Phase 7: Pregnancy Confirmation and Prenatal Follow-up
  Blood test for β-hCG 12–14 days after transfer. After confirming pregnancy, prenatal diagnosis (CVS or amniocentesis) is recommended to verify PGT results.

6. Interpretation of Key Diagnostic Indicators

7. Management of Special Situations

Robertsonian Translocation Carriers

PGT-SR can identify unbalanced translocation embryos, but attention must be paid to breakpoint locations. Some centers use SNP arrays to distinguish balanced carriers from normal embryos, but technical sensitivity is limited.

Reciprocal Translocation Carriers

Genetic counseling is complex; evaluation of whether breakpoints are in gene-dense regions is needed. PGT-SR success depends on chromosome segment size; small segment translocations (<5 Mb) may be missed.

Management of Mosaic Embryos

Low-level mosaicism (<20%) may be considered for transfer, but prenatal diagnosis is mandatory. High-level mosaicism (>50%) is generally advised against. Full informed consent is required before transferring mosaic embryos.

Repeated PGT Cycles with No Euploid Embryos

Common in advanced maternal age or very low ovarian reserve. Options include: ① Using donor oocytes; ② Attempting mitochondrial replacement (strict ethical restrictions); ③ Adjusting ovarian stimulation protocol and trying again.

Mitochondrial Disease and Third-Party Assistance

Mitochondrial DNA mutations can be screened via PGT-M combined with PGT-A, but the technique is complex. Some countries permit mitochondrial donation, but ethical controversy is high, and only very few centers offer it.

8. Observations from Practitioners

In the field of overseas IVF for chromosomal abnormalities, the following phenomena are observed in practice:

• PGT is over-recommended: Some commercial centers recommend PGT to all patients, ignoring ovarian reserve and age. For patients with AMH <0.6 and age >43, the probability of obtaining a euploid embryo after PGT is below 10%; decisions must be cautious.
• Genetic counseling is severely inadequate: Most patients are unaware of PGT limitations (e.g., missing mosaicism, inability to detect all genetic diseases). Centers should provide independent genetic counselors rather than having sales representatives explain.
• Laboratory quality varies: Biopsy timing (D5 vs D6), number of biopsied cells, and testing platform (NGS vs aCGH vs SNP) all affect result accuracy. Request internal quality control data from the last 12 months.
• Success rate data is not transparent: Some centers selectively publish “pregnancy rate after PGT” without disclosing “live birth rate per initiated cycle.” Patients should request data stratified by age and indication.
• Fee structures are hidden: PGT costs often do not include re-biopsy, repeated testing, embryo cryopreservation, or subsequent transfer fees. A full cycle cost breakdown should be confirmed before signing the contract.